Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity

Next Previous
Search
Trial Profile

A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects Who Have Peripheral Ischemic Ulcers of the Lower Extremity

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Beperminogene perplasmid (Primary)
  • Indications Arteriosclerosis obliterans; Foot ulcer; Peripheral arterial disorders
  • Focus Therapeutic Use
  • Acronyms LEGEND 1 trial
  • Sponsors AnGes

    • Most Recent Events

    • 19 Nov 2024 According to an AnGes media release, this trial has been chosen to be presented at the (FS.04) Featured Science: Vascular Outcomes in the Spotlight for the American Heart Association's Scientific Sessions 2024, which has taken place in Chicago, IL; USA on Nov. 16-18, 2024
    • 09 Mar 2023 Status changed from recruiting to active, no longer recruiting, according to a AnGes media release.
    • 09 Mar 2023 According to an AnGes media release, the clinical trial data will be finalized after one year of follow-up after the initial administration of the drug and results of this clinical trial are expected to be finalized in fiscal 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top